9,802 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 9,802 shares of the biopharmaceutical company's stock, valued at approximately $625,000.

Several other institutional investors have also modified their holdings of the business. Smartleaf Asset Management LLC grew its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 12.5% during the first quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock valued at $120,000 after purchasing an additional 208 shares during the period. Baird Financial Group Inc. increased its stake in Halozyme Therapeutics by 2.0% during the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock valued at $532,000 after buying an additional 221 shares during the period. Portside Wealth Group LLC raised its holdings in Halozyme Therapeutics by 2.4% during the first quarter. Portside Wealth Group LLC now owns 9,317 shares of the biopharmaceutical company's stock worth $595,000 after purchasing an additional 222 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its stake in shares of Halozyme Therapeutics by 1.6% in the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after buying an additional 294 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity

In other news, Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the sale, the director owned 28,611 shares in the company, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $53.73, for a total transaction of $1,074,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $39,422,721.87. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,497 shares of company stock worth $2,405,284. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

HALO traded up $0.92 on Wednesday, hitting $53.84. The company had a trading volume of 2,217,354 shares, compared to its average volume of 1,752,058. The stock has a market cap of $6.63 billion, a price-to-earnings ratio of 14.32, a price-to-earnings-growth ratio of 0.35 and a beta of 1.15. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The company's fifty day moving average price is $55.81 and its 200 day moving average price is $56.51. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.79 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on HALO. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Finally, Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.